Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants

Clinical Pharmacology in Drug Development

Volumn 4, Issue 4, 2015, Pages 295-304

  Devineni, Damayanthi ^a   Murphy, Joseph ^a   Wang, Shean Sheng ^a   Stieltjes, Hans ^b   Rothenberg, Paul ^a   Scheers, Ellen ^b   Mamidi, Rao N V S ^a  

^a LLC   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Absolute bioavailability; AMS; Canagliflozin; Microtracer; Pharmacokinetics

Indexed keywords

CANAGLIFLOZIN; CARBON 14; DRUG METABOLITE; ANTIDIABETIC AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; DRUG MICRODOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PHYSICAL EXAMINATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RADIOACTIVITY; SINGLE DRUG DOSE; URINARY EXCRETION; VITAL SIGN; ADOLESCENT; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; CHEMISTRY; FECES; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CANAGLIFLOZIN; FECES; HEALTHY VOLUNTEERS; HEPATOBILIARY ELIMINATION; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; YOUNG ADULT;

EID: 84937023290     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.162     Document Type: Article

References (23)

1. Devineni D, Curtin CR, Polidori D, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2013; 53:601-610.
2. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012; 14:539-545.
3. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013; 36:2154-2161.
4. Canagliflozin (Invokana™) Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2013. Accessed on April 4, 2014; Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204042s000lbl.pdf.
5. Canagliflozin (Invokana™), Summary of Product Characteristics. Beerse, Belgium: Janssen-Cilag International NV. 2013. Accessed on April 4, 2014; Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002649/WC500156456.pdf.
6. Lappin G, Stevens L. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opin Drug Metab Toxicol. 2008; 4:1021-1033.
7. Vogel JS, Love AH. Quantitating isotopic molecular labels with accelerator mass spectrometry. Methods Enzymol. 2005; 402:402-422.
8. 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J Clin Pharmacol. 2005; 45:1198-1205.
9. Hah SS, Henderson PT, Turteltaub KW. Recent advances in biomedical applications of accelerator mass spectrometry. J Biomed Sci. 2009; 16:54.
10. 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol. 2013; 75:763-768.
11. European Medicines Agency (EMEA), Committee for Proprietary Medicainal Products (CPMP). Position paper on the non-clinical safety studies to support clinical trials with a single micro dose. 2003. Accessed on April 4, 2014; Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002720.pdf.
12. Strong JM, Dutcher JS, Lee WK, Atkinson AJ, Jr. Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method. Clin Pharmacol Ther. 1975; 18:613-622.
13. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). Guidance for Industry, Investigators, and Reviewers-Exploratory IND Studies. 2006. Accessed on April 4, 2014; Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078933.pdf.
14. Mamidi RN, Cuyckens F, Chen J, et al. Metabolism and excretion of canagliflozin in mice, rats, dogs and humans. Drug Metab Dispos. 2014; 42:903-916.
15. Devineni D, Vaccaro N, Murphy J, et al. Effects of rifampin, cyclosporine A, or probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2014; (accepted for publication).
16. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm Res. 2000; 17:1551-1557.
17. Viswanathan C, Bansal S, Booth B, et al. Workshop/conference report-quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J. 2007; 9:E30-E42.
18. Food and Drug Administration(FDA), Center for Drug Evaluation and Research (CDER), Guidance for Industry, Bioanalytical Methods Validation. 2001. Accessed on April 4, 2014. Available at: http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf.
19. Duchateau G, Cochrane B, Windebank S, et al. Absolute oral bioavailability and metabolic turnover of beta-sitosterol in healthy subjects. Drug Metab Dispos. 2012; 40:2026-2030.
20. Nisly SA, Kolanczyk DM, Walton AM. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes. Am J Health Syst Pharm. 2013; 70:311-319.
21. Miyaji Y, Ishizuka T, Kawai K, et al. Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. Drug Metab Pharmacokinet. 2009; 24:130-138.
22. Lappin G, Garner RC, Meyers T, Powell J, Varley P. Novel use of accelerator mass spectrometry for the quantification of low levels of systemic therapeutic recombinant protein. J Pharm Biomed Anal. 2006; 41:1299-1302.
23. Devineni D, Manitpisitkul P, Murphy J, et al. Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants. Clin Pharmacol Drug Dev. 2014. DOI: 10.1002/cpdd.151